I like these responses and debates
From Colin
F. Perry Wilson, this is great stuff. Super helpful. I am going to use this. The problem with this search is that no doctor is using Hydroxychloroquine (that believes in its efficacy) alone. This is what troubles me. Listening to these Dr.s for 2 minutes you would hear ZINC several times as part of the "cocktail". It really bothers those seeking the truth, that you would ignore Zinc in any of your searches. It is also troubling that none of the studies seem to be using Zinc when that is an integral part of the protocol (again according to these Dr.s). Supposedly, Hydroxychlororquine is the bridge and Zinc is the agent that uses that bridge to adversely affect COVID-19's ability to replicate. They use Azithromycin too, for what purpose, I have no idea. I have NO IDEA if this regimen actually works! But what I do know is that you delivered great advice on how to search for a protocol that none of these "Frontline" Dr.s seem to be using. You might find similar results adding ZINC & Azithromycin to the search field, but at least you would be searching for the actual protocol. This seems like a study that is trying to test the cocktail, no results yet.
https://clinicaltrials.gov/ct2/show/NCT04370782From Chris
Dr Wilson, might I respectfully suggest that you investigate how hydroxychloroquine's functionality as a TLR 7/8/9 antagonist contributes to its utility in combating COVID-19? The PubMed research you mentioned in this video tends to be flawed specifically in the Methods sections. Clinical investigations are too coarsely put together, given that the proposed mechanism of action for HCQ combating COVID-19 is dubious at best; statistical analyses as also highly suspect, due to low sample size, short duration of investigation, and missing data. HCQ is by no means a cure for COVID-19 anymore than, say, aspirin (or any NSAID) is a cure for pneumonia. But like NSAIDs for pneumonia, HCQ does have some level of justification as a treatment arm for this pandemic, as do any medications that act as TLR 7/8/9 antagonists; they have an immuno-modulatory effect that can potentially prevent ARDS from setting in if administered properly, thus stabilizing the patient so they can better combat the infection for its duration. All of this of course needs to thoroughly investigated in much better-structured studies. And there will certainly be better, more focused drug options devised over time. All that said, I find this politicization of HCQ in the media off-putting to say the least. Anyway, those are my two cents.
